What we do:
Therapeutic proteins: technology, product development & manufacture
Client: Apposite Capital, experienced private equity and venture capital investors dedicated to life sciences and healthcare www.appositecapital.com considering co-investment in a West Coast US biotech company, Anaphore.
Ithaka’s role:
- Due diligence – to provide an opinion on aspects of a novel therapeutic platform as an alternative to antibody-based therapeutics.
Results:
- Apposite Capital, 5AM Ventures & Versant Ventures led a $25M investment in Anaphore in January 2009.
Client: Multinational chemical and biopharmaceutical synthesis and manufacturing organisation. Revenues £1.66B in 2008.
Ithaka’s role:
- Advice on underlying science and interpretation of IP on an aspect of biopharmaceutical design.
Results:
- development of strategy to address IP issues.
Client: Multinational pharmaceutical company with significant biopharmaceutical interests. Revenues £3.1B in 2008.
Ithaka’s role:
- Survey of intellectual property in a particular area of biopharmaceutical development.
Results:
- Confidential assignment which informed and supported development of corporate strategy in this area.
Client: Wellcome Trust considering investment in Kymab, a spin-out from the Sanger Institute in Cambridge.
Ithaka’s role:
- To contribute to the technical due diligence process assessing Kymab’s plans and novel technology for generating antibodies. (The Company is using embryonic stem cell technology to develop its Kymouse™ platform to generate novel antibody-based biopharmaceuticals.)
Results:
- A £20M equity funding round by the Wellcome Trust investment division in Kymab.